Display options
Cite
Scurt FG, Menne J, Brandt S, et al. Systemic Inflammation Precedes Microalbuminuria in Diabetes. Kidney Int Rep. 2019;4(10):1373-1386doi: 10.1016/j.ekir.2019.06.005.
Scurt, F. G., Menne, J., Brandt, S., Bernhardt, A., Mertens, P. R., Haller, H., Chatzikyrkou, C. (2019). Systemic Inflammation Precedes Microalbuminuria in Diabetes. Kidney international reports, 4(10), 1373-1386. https://doi.org/10.1016/j.ekir.2019.06.005
Scurt, Florian G, et al. "Systemic Inflammation Precedes Microalbuminuria in Diabetes." Kidney international reports vol. 4,10 (2019): 1373-1386. doi: https://doi.org/10.1016/j.ekir.2019.06.005
Scurt FG, Menne J, Brandt S, Bernhardt A, Mertens PR, Haller H, Chatzikyrkou C. Systemic Inflammation Precedes Microalbuminuria in Diabetes. Kidney Int Rep. 2019 Jun 21;4(10):1373-1386. doi: 10.1016/j.ekir.2019.06.005. eCollection 2019 Oct. PMID: 31701047; PMCID: PMC6829192.
Copy Download .nbib Format: NLM
Share it on

Kidney Int Rep. 2019 Jun 21;4(10):1373-1386. doi: 10.1016/j.ekir.2019.06.005. eCollection 2019 Oct.

Systemic Inflammation Precedes Microalbuminuria in Diabetes.

Kidney international reports

Florian G Scurt, Jan Menne, Sabine Brandt, Anja Bernhardt, Peter R Mertens, Hermann Haller, Christos Chatzikyrkou,

Affiliations

  1. Clinic of Nephrology, Hypertension, Diabetes and Endocrinology, Health Campus Immunology, Infectiology, and Inflammation, Otto-von-Guericke University, Magdeburg, Germany.
  2. Nephrology Section, Hanover Medical School, Hanover, Germany.

PMID: 31701047 PMCID: PMC6829192 DOI: 10.1016/j.ekir.2019.06.005

Abstract

AIM: The aim of the case-control study was to investigate if serum biomarkers indicative of vascular inflammation and endothelial dysfunction can predict the development of microalbuminuria in patients with diabetes mellitus type 2.

METHODS: Among participants enrolled in the ROADMAP (Randomized Olmesartan And Diabetes MicroAlbuminuria Prevention) and observational follow-up (OFU) studies, a panel of 15 serum biomarkers was quantified from samples obtained at initiation of the study and tested for associations with the development of new-onset microalbuminuria during follow-up. A case-control study was conducted with inclusion of 172 patients with microalbuminuria and 188 matched controls. Nonparametric inferential, nonlinear regression, mediation, and bootstrapping statistical methods were used for the analysis.

RESULTS: The median follow-up time was 37 months. At baseline, mean concentrations of C-X-C motif chemokine ligand 16 (CXCL-16), transforming growth factor (TGF)-β1 and angiopoietin-2 were higher in patients with subsequent microalbuminuria. In the multivariate analysis, after adjustment for age, sex, body mass index, glycated hemoglobin, duration of diabetes, low-density lipoprotein (LDL), smoking status, blood pressure, baseline urine albumin-to-creatinine ratio (UACR), estimated glomerular filtration rate (eGFR), time of follow-up and cardiovascular disease, CXCL-16 (odds ratio [OR] 2.60, 95% confidence interval [CI] 1.71-3.96), angiopoietin-2 (OR 1.50, 95% CI 1.14-1.98) and TGF-β1 (OR 1.03, 95% CI 1.01-1.04) remained significant predictors of new-onset microalbuminuria (

CONCLUSION: In patients with type 2 diabetes, elevated plasma levels of CXCL-16, angiopoietin-2, and TGF-β1 are independently predictive of microalbuminuria. Thus, these serum markers improve renal risk models beyond established clinical risk factors.

© 2019 International Society of Nephrology. Published by Elsevier Inc.

Keywords: albuminuria; atheromatosis; cardiovascular disease; diabetic kidney disease; inflammation

References

  1. Am J Physiol Renal Physiol. 2016 Apr 1;310(7):F596-F606 - PubMed
  2. Eur J Clin Invest. 2011 Aug;41(8):836-45 - PubMed
  3. PLoS One. 2014 Jan 29;9(1):e87786 - PubMed
  4. Diabetes Care. 2014;37(3):867-75 - PubMed
  5. Eur J Appl Physiol. 2007 Sep;101(2):263-4; author reply 265-6 - PubMed
  6. Am J Physiol Heart Circ Physiol. 2016 Sep 1;311(3):H815-21 - PubMed
  7. J Hypertens. 2010 Oct;28(10):1983-94 - PubMed
  8. Am J Pathol. 2009 Jun;174(6):2061-72 - PubMed
  9. J Cell Mol Med. 2009 Sep;13(9B):3809-25 - PubMed
  10. Stat Med. 2008 Jan 30;27(2):157-72; discussion 207-12 - PubMed
  11. Kidney Int. 2017 Aug;92(2):388-396 - PubMed
  12. Kidney Int. 2016 Dec;90(6):1175-1183 - PubMed
  13. J Am Heart Assoc. 2014;3(2):e000810 - PubMed
  14. Nat Rev Nephrol. 2018 Jun;14(6):361-377 - PubMed
  15. PLoS One. 2014 Oct 03;9(10):e108862 - PubMed
  16. Malawi Med J. 2012 Sep;24(3):69-71 - PubMed
  17. PLoS One. 2013;8(3):e54668 - PubMed
  18. Circ Res. 2012 Oct 26;111(10):1297-307 - PubMed
  19. Nat Med. 2006 Feb;12(2):235-9 - PubMed
  20. Cytokine. 2019 Oct;122:154081 - PubMed
  21. Circulation. 2015 Dec 15;132(24):2297-304 - PubMed
  22. J Am Soc Nephrol. 2015 Aug;26(8):1999-2010 - PubMed
  23. Stat Med. 1996 Feb 28;15(4):361-87 - PubMed
  24. J Am Soc Nephrol. 2017 Apr;28(4):1050-1061 - PubMed
  25. Am J Pathol. 2007 May;170(5):1485-96 - PubMed
  26. J Hypertens. 2017 Dec;35(12):2501-2509 - PubMed
  27. Nat Rev Nephrol. 2011 Jun;7(6):327-40 - PubMed
  28. J Hypertens. 2009 Aug;27(8):1641-7 - PubMed
  29. Kidney Int. 2016 Jul;90(1):149-56 - PubMed
  30. Arterioscler Thromb Vasc Biol. 2011 May;31(5):969-79 - PubMed
  31. Multivariate Behav Res. 2001 Apr 1;36(2):249-77 - PubMed
  32. Kidney Int. 2013 Feb;83(2):278-84 - PubMed
  33. N Engl J Med. 2009 Jul 2;361(1):40-51 - PubMed
  34. J Am Soc Nephrol. 2011 Oct;22(10):1876-86 - PubMed
  35. N Engl J Med. 2011 Mar 10;364(10):907-17 - PubMed
  36. Diabetes Care. 2013 Nov;36(11):3620-6 - PubMed
  37. Clin J Am Soc Nephrol. 2017 Aug 7;12(8):1226-1235 - PubMed
  38. Int J Endocrinol. 2015;2015:163120 - PubMed
  39. J Immunol. 2004 May 15;172(10):6362-72 - PubMed
  40. J Am Soc Nephrol. 2017 Jul;28(7):1973-1982 - PubMed
  41. N Engl J Med. 2017 Sep 21;377(12):1119-1131 - PubMed
  42. Can J Kidney Health Dis. 2017 May 22;4:2054358117705371 - PubMed
  43. Kidney Int. 2017 Jul;92(1):258-266 - PubMed
  44. Br J Pharmacol. 2009 Jul;157(6):994-1003 - PubMed
  45. JAMA. 2016 Aug 9;316(6):602-10 - PubMed
  46. Kidney Blood Press Res. 2016;41(5):663-671 - PubMed
  47. J Am Soc Nephrol. 2007 Aug;18(8):2320-9 - PubMed
  48. Nephrol Dial Transplant. 2014 Jan;29(1):109-18 - PubMed
  49. N Engl J Med. 2014 Apr 17;370(16):1514-23 - PubMed
  50. Clin Immunol. 2016 Sep;170:61-9 - PubMed
  51. Hypertension. 2013 Dec;62(6):1129-37 - PubMed
  52. Atherosclerosis. 2015 Aug;241(2):297-304 - PubMed
  53. Kidney Int. 2017 Jun;91(6):1300-1311 - PubMed
  54. Nephrol Dial Transplant. 2012 May;27(5):1867-72 - PubMed
  55. J Am Soc Nephrol. 2009 Feb;20(2):436-43 - PubMed
  56. J Am Soc Nephrol. 2017 Dec;28(12):3490-3503 - PubMed
  57. Diabetologia. 2016 Aug;59(8):1616-20 - PubMed
  58. J Am Soc Nephrol. 2017 Mar;28(3):953-962 - PubMed
  59. Circ Res. 2016 Jul 8;119(2):330-40 - PubMed
  60. BMC Nephrol. 2017 Mar 21;18(1):98 - PubMed
  61. Diabetes Care. 2004 Dec;27(12):2918-24 - PubMed
  62. Psychol Methods. 2002 Dec;7(4):422-45 - PubMed
  63. Kidney Int. 2018 Feb;93(2):439-449 - PubMed
  64. Clin J Am Soc Nephrol. 2017 Aug 7;12(8):1366-1373 - PubMed
  65. Annu Rev Pharmacol Toxicol. 2002;42:469-99 - PubMed
  66. Lancet. 2012 Nov 10;380(9854):1662-73 - PubMed
  67. Vasc Med. 2002 Feb;7(1):35-43 - PubMed
  68. Clin Chim Acta. 2005 Sep;359(1-2):1-26 - PubMed
  69. Sci Rep. 2016 Dec 19;6:39400 - PubMed
  70. Diabetes. 2007 Feb;56(2):380-8 - PubMed
  71. J Am Soc Nephrol. 2017 Apr;28(4):1023-1039 - PubMed

Publication Types